ÂÜÀòÂÒÂ×

Kjell Mortier is a seasoned professional in the life sciences sector, currently serving as a Fund Manager at Novalis Biotech since February 2019, focusing on early-stage venture capital investments in healthcare technologies. Kjell also holds board member positions at BioLizard, RheaVita BVBA, and Epify BV, while owning Mobio Consult. Prior experience includes leading analytical science at Eurofins Amatsigroup and developing analytical methods at Ablynx and AnaBioTec, along with a supervisory role in continuous improvement at Baxter BioScience. Kjell Mortier earned a degree in Pharmaceutical Sciences from Ghent University and is furthering education at Vlerick Business School and EHSAL Management School.